Understanding and preventing drug-drug and drug-gene interactions

Expert Review of Clinical Pharmacology

Volumn 7, Issue 4, 2014, Pages 533-544

  Tannenbaum, Cara ^a   Sheehan, Nancy L ^b  

^a CENTRE DE RECHERCHE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

cytochrome mediated drug interactions; drug transporters; drug drug gene interactions; pharmacogenomics; polypharmacy

Indexed keywords

AMIODARONE; ATAZANAVIR; BILE ACID; BREAST CANCER RESISTANCE PROTEIN; CHOLESTEROL; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIGOXIN; ERYTHROMYCIN; GEMFIBROZIL; MULTIDRUG RESISTANCE PROTEIN; NUCLEOSIDE TRANSPORTER; OMEPRAZOLE; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; PAROXETINE; PRAVASTATIN; RIFAMPICIN; RITONAVIR; ROSUVASTATIN; VORICONAZOLE; CYTOCHROME P450;

ADVERSE DRUG REACTION; AREA UNDER THE CURVE; DECISION SUPPORT SYSTEM; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DRUG INTERACTION; DRUG GENE INTERACTION; DRUG INTERACTION; DRUG LABELING; DRUG MECHANISM; DRUG METABOLISM; GENETIC POLYMORPHISM; GENOTYPE; GLUCURONIDATION; HUMAN; HYPERBILIRUBINEMIA; KIDNEY CLEARANCE; NONHUMAN; PREVALENCE; RESPIRATION DEPRESSION; REVIEW; RHABDOMYOLYSIS; STOMACH PH; TISSUE DISTRIBUTION; TREATMENT RESPONSE; WITHDRAWAL SYNDROME; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETICS; METABOLISM; PHARMACOGENETICS; PROCEDURES; RISK;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PHARMACOGENETICS; RISK;

EID: 84903131070     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.910111     Document Type: Review

References (98)

1. Huang SM, Strong JM, Zhang L, et al. New era in Drug interaction evaluation: US FDA update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 2008;48(6):662-70 (Pubitemid 351713150
2. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990;264(21):2788-90
3. US FDA. Guidance for Industry: Drug metabolism/drug interactions in the drug development process: Studies in vitro. 1997. Available from: Www.fda.gov/cder/guidance/ clin3.pdf [Last accessed 21 February 2013]
4. US FDA. Guidance for Industry: In vivo metabolism/drug interaction: Study design, data analysis and recommendation for dosing and labeling. 1999. Available from: Www.fda.gov/cder/guidance/2635fnl.pdf [Last accessed 21 February 2013]
5. Huang SM, Temple R, Throckmorton DC, Lesko LJ. Drug interaction studies: Study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 2007;81(2):298-304 (Pubitemid 46174829
6. Glintborg B, Andersen SE, Dalhoff K. Drug-drug interactions among recently hospitalised patients-frequent but mostly clinically insignificant. Eur J Clin Pharmacol 2005;61(9):675-81
7. Doucet J, Chassagne P, Trivalle C, et al. Drug-drug interactions related to hospital admissions in older adults: A prospective study of 1000 patients. J Am Geriatr Soc 1996;44(8):944-8 (Pubitemid 26287151
8. Malone DC, Hutchins DS, Haupert H, et al. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm 2005; 62(19):1983-91 (Pubitemid 41416234
9. Hines LE, Malone DC, Murphy JE. Recommendations for generating, evaluating, and implementing drug-drug interaction evidence. Pharmacotherapy 2012;32(4):304-13
10. Zakrzewski-Jakubiak H, Doan J, Lamoureux P, et al. Detection and prevention of drug-drug interactions in the hospitalized elderly: Utility of new cytochrome P450-based software. Am J Geriatr Pharmacother 2011;9(6):461-70
11. Lapane KL, Waring ME, Schneider KL, et al. A mixed method study of the merits of e-prescribing drug alerts in primary care. J Gen Intern Med 2008;23(4):442-6 (Pubitemid 351464878
12. Magnus D, Rodgers S, Avery AJ. GPs' views on computerized drug interaction alerts: Questionnaire survey. J Clin Pharm Ther 2002;27(5):377-82 (Pubitemid 35286237
13. Monane M, Matthias DM, Nagle BA, Kelly MA. Improving prescribing patterns for the elderly through an online drug utilization review intervention: A system linking the physician, pharmacist, and computer. JAMA 1998;280(14):1249-52 (Pubitemid 28469231
14. Shapiro LE, Shear NH. Drug interactions: Proteins, pumps, and P-450s. J Am Acad Dermatol 2002;47(4):467-84.quiz 485-8
15. Kis O, Robillard K, Chan GN, Bendayan R. The complexities of antiretroviral drug-drug interactions: Role of ABC and SLC transporters. Trends Pharmacol Sci 2010; 31(1):22-35
16. Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: Function and regulation. Pharmacol Rev 2010;62(1):1-96
17. Pedersen JM, Matsson P, Bergstrom CA, et al. Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci 2013;136(2):328-43
18. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153(14):1665-70 (Pubitemid 23217872
19. Lehto P, Kivisto KT, Neuvonen PJ. The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin. Br J Clin Pharmacol 1994;37(1):82-5 (Pubitemid 24204588
20. Zhu L, Persson A, Mahnke L, et al. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects. J Clin Pharmacol 2011;51(3):368-77
21. Kolars JC, Lown KS, Schmiedlin-Ren P, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994;4(5): 247-59 (Pubitemid 24337433
22. Wu CY, Benet LZ, Hebert MF, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol Ther 1995;58(5):492-7
23. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004;76(2):167-77 (Pubitemid 39013406
24. van Heeswijk R, Verboven P, Vandevoorde A, et al. Pharmacokinetic interaction between telaprevir and methadone. Antimicrob Agents Chemother 2013;57(5):2304-9
25. Clarke SE, Jones BC. Human cytochromes P450 and their role in metabolism-based drug-drugs interactions. In: Rodrigues AD, editor. Drug-drug interaction. Inform Healthcare; NY, USA: 2008. p. 53-85
26. Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: A review. Am J Geriatr Pharmacother 2011; 9(6):364-77
27. Lertora JJ, Rege AB, Greenspan DL, et al. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1994;56(3): 272-8 (Pubitemid 24323918
28. Antoniou T, Gough K, Yoong D, Arbess G. Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid. Clin Infect Dis 2004;38(5):e38-40
29. Rowland A, Elliot DJ, Williams JA, et al. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 2006;34(6):1055-62
30. Morris RG, Black AB, Lam E, Westley IS. Clinical study of lamotrigine and valproic acid in patients with epilepsy: Using a drug interaction to advantage?. Ther Drug Monit 2000;22(6):656-60
31. Huang CW, Tsai JJ, Lai ML. Lamotrigine-related skin rashes in adults. Kaohsiung J Med Sci 2002;18(11):566-72
32. Ebert U, Thong NQ, Oertel R, Kirch W. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur J Clin Pharmacol 2000;56(4):299-304 (Pubitemid 30462927
33. Gallicano KD, Sahai J, Shukla VK, et al. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol 1999;48(2):168-79 (Pubitemid 29349452
34. Wakasugi H, Yano I, Ito T, et al. Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein. Clin Pharmacol Ther 1998;64(1):123-8 (Pubitemid 28377338
35. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003;73(6):538-44 (Pubitemid 37249124
36. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94(1):13-20 (Pubitemid 23021166
37. Nakagomi-Hagihara R, Nakai D, Tokui T. Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica 2007;37(4):416-26 (Pubitemid 46572887
38. Seripa D, Pilotto A, Panza F, et al. Pharmacogenetics of cytochrome P450 (CYP) in the elderly. Ageing Res Rev 2010; 9(4):457-74
39. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II. Clin Pharmacokinet 2009;48(12):761-804
40. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: A recent update on clinical implications and endogenous effects. Pharmacogenomics J 2013;13(1):1-11 Anal Bioanal Chem 2008;392(6):1093-108
41. Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: A systematic review and meta-Analysis. JAMA 2011;306(24): 2704-14
42. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009;302(13): 1429-36
43. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014. Clin Pharmacol Ther 2014;95(4):376-82
44. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: A population based cohort study. BMJ 2010;340:c693
45. Ehmer U, Kalthoff S, Fakundiny B, et al. Gilbert syndrome redefined: A complex genetic haplotype influences the regulation of glucuronidation. Hepatology 2012;55(6): 1912-21
46. Lankisch TO, Moebius U, Wehmeier M, et al. Gilbert's disease and atazanavir: From phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 2006;44(5):1324-32 (Pubitemid 44748383
47. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22(8):1382-8 (Pubitemid 41103619
48. Lankisch TO, Schulz C, Zwingers T, et al. Gilbert's Syndrome and irinotecan toxicity: Combination with UDPglucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev 2008;17(3):695-701 (Pubitemid 351469222
49. Izzedine H, Hulot JS, Villard E, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006;194(11): 1481-91 (Pubitemid 44851889
50. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003; 31(5):540-7 (Pubitemid 36444162
51. Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics 2011;12(6):861-72
52. Zhu L, Uy J, Brüggemann R, et al. CYP2C19 genotype-dependent pharmacokinetic drug interaction between voriconazole and ritonavir boosted atazanavir in healthy subjects [abstract O-08]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2012; Barcelona, Spain
53. Preskorn SH, Kane CP, Lobello K, et al. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: Implications for personalized medicine. J Clin Psychiatry 2013;74(6): 614-21
54. Fischer HD, Juurlink DN, Mamdani MM, et al. Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: A population-based study. Arch Intern Med 2010;170(7):617-21
55. Schelleman H, Bilker WB, Brensinger CM, et al. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: Interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther 2008;84(5):581-8
56. Antoniou T, Gomes T, Mamdani MM, Juurlink DN. Trimethoprim/ sulfamethoxazole-induced phenytoin toxicity in the elderly: A population-based study. Br J Clin Pharmacol 2011;71(4):544-9
57. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003;289(13):1652-8 (Pubitemid 37430270
58. Schelleman H, Bilker WB, Brensinger CM, et al. Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide. Clin Pharmacol Ther 2010;88(2): 214-22
59. Wright AJ, Gomes T, Mamdani MM, et al. The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. CMAJ 2011; 183(3):303-7
60. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004;13(7):417-26 (Pubitemid 38996852
61. US FDA. USA Department of Health and Human Services. Guidance for Industry. Drug Interaction Studies - Study design, data analysis, implications for dosing, and labeling recommendations. Drafts Guidance. 2012. Available from: Www.fda.gov/ downloads/Drugs/GuidanceCompliance RegulatoryInformation/ Guidances/ UCM292362.pdf [Last accessed 5 August 2013]
62. Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: A study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 2007;30(10):911-18 (Pubitemid 47481446
63. Doan J, Zakrzewski-Jakubiak H, Roy J, et al. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother 2013;47(3):324-32
64. Davies SJ, Eayrs S, Pratt P, Lennard MS. Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol 2004;57(4):464-72 (Pubitemid 38519652
65. Mulder H, Heerdink ER, van Iersel EE, et al. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in Different populations: A cross-sectional study. Ann Pharmacother 2007;41(3):408-13 (Pubitemid 46536030
66. Mann HJ. Drug-Associated disease: Cytochrome P450 interactions. Crit Care Clin 2006;22(2):329-45 Identification of serious drug-drug interactions: Results of the partnership to prevent drug-drug interactions. J Am Pharm Assoc 2003;2004:44(2):142-51
67. Andersson ML, Lindh JD, Mannheimer B. The impact of interacting drugs on Dispensed doses of warfarin in the Swedish population: A novel use of population based drug registers. J Clin Pharmacol 2013; 53(12):1322-7
68. Andersson ML, Bottiger Y, Lindh JD, et al. Impact of the drug-drug interaction Database SFINX on prevalence of potentially serious drug-drug interactions in primary health care. Eur J Clin Pharmacol 2013; 69(3):565-71
69. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. E7 Studies in support of special populations: Geriatrics Questions and Answers. 2012. Available from: Www/ich. org/fileadmin/Public-Web-Site/ ICH-Products/Guidelines/Efficacy/ E7-Q-As/E7-Q-As-step4.pdf [Last accessed 2 March 2013]
70. Anthony M, Romero K, Malone DC, et al. Warfarin interactions with substances listed in Drug information compendia and in the FDA-Approved label for warfarin sodium. Clin Pharmacol Ther 2009;86(4)):425-9
71. Boyce RD, Collins C, Clayton M, et al. Inhibitory metabolic drug interactions with newer psychotropic drugs: Inclusion in package inserts and influences of concurrence in Drug interaction screening software. Ann Pharmacother 2012;46(10): 1287-98
72. Boyce RD, Handler SM, Karp JF, Hanlon JT. Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: A comparison of evidence-based literature and package insert information. Am J Geriatr Pharmacother 2012;10(2):139-50
73. DiNicolantonio JJ, Serebruany VL. Challenging the FDA black box warning for high aspirin Dose with ticagrelor in patients with diabetes. Diabetes 2013;62(3):669-71
74. Ridgely MS, Greenberg MD. Too many alerts, too much liability: Sorting through the malpractice implications of drug-drug interaction clinical decision support. St Louis U J Health L & Pol'y 2012;5(2): 257-96
75. Marroum PJ, Uppoor RS, Parmelee T, et al. In vivo drug-drug interaction studies-A survey of all new molecular entities approved from 1987;Clin Pharmacol Ther 2000;68(3):280-5
76. Yoshida N, Yamada A, Mimura Y, et al. Trends in new drug interactions for pharmaceutical products in Japan. Pharmacoepidemiol. Drug Saf 2006;15(6): 421-7 (Pubitemid 44018701
77. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-Anticoagulant effect of warfarin. Blood 2005;105(2):645-9 (Pubitemid 40070748
78. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008;84(3):326-31
79. Gong IY, Tirona RG, Schwarz UI, et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 2011;118(11):3163-71
80. Anderson JL, Horne BD, Stevens SM, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin Dosing (CoumaGen-II). Circulation 2012;125(16):1997-2005
81. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin Dosing. Clin Pharmacol Ther 2011; 90(4):625-9
82. de Denus S, Letarte N, Hurlimann T, et al. An evaluation of pharmacists' expectations towards pharmacogenomics. Pharmacogenomics 2013;14(2):165-75
83. Mills R, Voora D, Peyser B, Haga SB. Delivering pharmacogenetic testing in a primary care setting. Pharmgenomics Pers Med 2013;6:105-12
84. Abarca J, Colon LR, Wang VS, et al. Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies. J Manag Care Pharm 2006;12(5):383-9 (Pubitemid 47400595
85. Sweidan M, Reeve JF, Brien JA, et al. Quality of drug interaction alerts in prescribing and dispensing software. Med J Aust 2009;190(5):251-4
86. Saverno KR, Hines LE, Warholak TL, et al. Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions. J Am Med Inform Assoc 2011; 18(1):32-7
87. Smithburger PL, Buckley MS, Bejian S, et al. A critical evaluation of clinical decision support for the detection of drug-drug interactions. Expert Opin Drug Saf 2011;10(6):871-82
88. Duke JD, Bolchini D. A successful model and visual design for creating context-Aware drug-drug interaction alerts. AMIA Annu Symp Proc 2011;2011:339-48
89. Intermed-Rx application. Available from: Http://ws-ddi.intermed-rx.ca
90. Sheehan NL, Kelly DV, Tseng AL, et al. Evaluation of HIV drug interaction web sites. Ann Pharmacother 2003;37(11): 1577-86 (Pubitemid 37315094
91. Tamblyn R, Huang A, Taylor L, et al. A randomized trial of the effectiveness of on-demand versus computer-Triggered drug decision support in primary care. J Am Med Inform Assoc 2008;15(4):430-8 (Pubitemid 351885165
92. Floor-Schreudering A, Geerts AF, Aronson JK, et al. Checklist for standardized reporting of drug-drug interaction management guidelines. Eur J Clin Pharmacol 2014;70(3): 313-18
93. Antoniou T, Gomes T, Mamdani MM, Juurlink DN. Ciprofloxacin-induced theophylline. toxicity: A population-based study. Eur J Clin Pharmacol 2011;67(5): 521-6
94. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: Potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003;46(3):347-51 (Pubitemid 36547589
95. LeBel M, Masson E, Guilbert E, et al. Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone. J Clin Pharmacol 1998; 38(11):1042-50 (Pubitemid 28524452
96. Skolnick JL, Stoler BS, Katz DB, Anderson WH. Rifampin, oral contraceptives, and pregnancy. JAMA 1976; 236(12):1382
97. Patel AM, Shariff S, Bailey DG, et al. Statin toxicity from macrolide antibiotic coprescription: A population-based cohort study. Ann Intern Med 2013;158(12): 869-76
98. Schwarze-Zander C, Klingmuller D, Klumper J, et al. Triamcinolone and ritonavir leading to drug-induced Cushing syndrome and adrenal suppression: Description of a new case and review of the literature. Infection 2013;41(6): 1183-7